- Preparation method and application of 2, 3, 4, 6-tetra-O-trimethylsilyl-D-glucolactone
-
The invention relates to the technical field of medicine, in particular to a preparation method and application of 2, 3, 4, 6-tetra-O-trimethylsilyl-D-gluconolactone. According to the preparation method, D-gluconolactone and hexamethyldisilazane react in an ionic liquid, cations in the ionic liquid are alkyl imidazolium ions, and anions in the ionic liquid are hexafluorophosphate radicals, tetrafluoroborate radicals, tetrachloroaluminate radicals or chloride ions. The ionic liquid is stable during high-temperature distillation, the solvent after reaction can be recycled, the preparation methodhas few reaction steps, atom economy is high, and operation conditions are easy to control. The preparation method can be used for preparing canagliflozin.
- -
-
Paragraph 0020-0055
(2021/02/10)
-
- Preparation method for polyhydroxy carbohydrate compound
-
The invention discloses a preparation method and post-treatment method for a trimethylsilyl protecting group of a polyhydroxy carbohydrate compound. According to the preparation method, a reaction occurs by taking the polyhydroxy carbohydrate compound as a raw material, dichloromethane, tetrahydrofuran, methylbenzene and methyl tert-butyl ether as solvents and a halogen elementary substance or a halogen-containing trimethyl reagent as a catalyst; then a protecting group compound is added, and the temperature is controlled to be 0-60 DEG C; and finally, an adsorbent is added into a reaction solution, and filtering is performed to obtain the product. The simple-to-operate preparation method for the trimethylsilyl protecting groups on polyhydroxy saccharide and a polyhydroxy natural product has the advantages that the raw and auxiliary materials are few; the cost is low; post-treatment is simple; a way of post-treatment with water is avoided; and the used catalyst is completely removed byadopting the multi-pore activated carbon and multi-pore ion resin, thus guaranteeing the stability increase of the product.
- -
-
Paragraph 0058-0060; 0061-0063; 0094-0096; 0112-0114
(2021/01/24)
-
- Synthesis method and application of 1-methyl glucose
-
The invention discloses a synthesis method and application of 1-methyl glucose. The synthesis method comprises the following steps: dissolving gluconic acid delta-lactone in THF, adding N-methylmorpholine and TMSCl, reacting to obtain TMS-protected gluconic acid delta-lactone, dissolving the TMS-protected gluconic acid delta lactone in anhydrous THF, treating with methyl lithium or methyl magnesium bromide, reacting to obtain TMS-protected 1-methyl glucose, dissolving the TMS-protected 1-methyl glucose in acetonitrile-water, and removing TMS protection by adding H strong cation exchangeresin to obtain 1-methyl glucose. The effect of applying 1-methyl glucose to cigarette perfuming is mainly to improve the aroma quality and aroma quantity, reduce irritation and purify the aftertaste.
- -
-
Paragraph 0024-0028
(2021/01/29)
-
- Preparation method and preparation of C-glycoside derivative
-
The invention relates to a preparation method of a co-crystal containing (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and L-proline, and a pharmaceutical preparation of the co-crystal. A preparation method is low in impurity content, high in yield and especially suitable for preparation of the pharmaceutical preparation. The preparation obtained by using the co-crystal prepared by the method has good stability and dissolubility, and can effectively achieve the curative effects of treating diabetes mellitus and reducing blood sugar as an SGLT-2 inhibitor drug; the pharmaceutical composition can meet the requirements of clinical medication and has good safety.
- -
-
Paragraph 0040
(2021/07/01)
-
- Telescoped lithiation, C-arylation and methoxylation in flow-batch hybrid toward the synthesis of canagliflozin
-
We report a highly efficient three-step flow-batch hybrid procedure for the synthesis of a key canagliflozin intermediate. The telescoped process provides exquisite control over an exothermic and mixing sensitive lithiation and subsequent C-arylation within a microstructured flow reactor. Methoxylation reagents are then added in flow, before reaching completion in a batch vessel. The flow process afforded the target intermediate in 76% yield, with a throughput of 26.8 g/h.
- Hone, Christopher A.,Oliver Kappe, C.,Polterauer, Dominik,Williams, Jason D.
-
supporting information
(2021/09/22)
-
- Method for synthesizing diabetes medicine by D - gluconic acid - δ δ-lactone
-
The invention discloses a method for synthesizing a diabetes drug by D - gluconic acid - δ δ-lactone. To the technical field of drug synthesis, D - glucose acid - δ δ-lactone is used as a raw material, and then subjected to catalytic hydrogenation and bromination reaction through three-silyl protecting reaction, then condensed with 5 - bromo -2 - chloro -4’ - ethoxy diphenyl methane, and finally, trimethyl silicon-based protection is removed. To the method for synthesizing the diabetes medicine by D - gluconic acid - δ δ-lactone, D - gluconic acid - δ δ-lactone is adopted as the starting raw material, the reaction process is simple, the intermediate is easy to purify, and the raw materials used in the reaction are easily obtained. The reaction process is more mild than the prior art. The yield of the final product can reach 95.89% or above, and the purity can reach 99.5% or more.
- -
-
Paragraph 0044-0048; 0066-0069; 0083-0086; 0100-0103; ...
(2021/11/10)
-
- Preparation method of 2, 3, 4, 6-tetra-O-trimethylsilyl-D-glucolactone
-
The present invention provides a preparation method of 2, 3, 4, 6-tetra-O-trimethylsilyl-D-glucolactone. The method comprises the following steps: dropwise adding trimethylchlorosilane into a system of tetrahydrofuran and N-methylmorpholine, adding glucolactone in batches after dropwise adding of the trimethylchlorosilane, and then adding 4-dimethyl pyridine for reaction so as to obtain the 2, 3,4, 6-tetra-O-trimethylsilyl-D-glucolactone. Compared with the prior art, the preparation method disclosed by the invention has the advantages that the requirements on the feeding temperature and the feeding time during reaction are wider, the quality controllable range is widened, the process repeatability is good, the requirement on the cooling of production equipment is reduced, and the preparation method has great advantages in the aspects of product purity and impurity compound IV control.
- -
-
Paragraph 0040-0049
(2020/06/20)
-
- A Concise and Efficient Synthesis of Dapagliflozin
-
A concise and efficient synthesis of the SGLT-2 inhibitor dapagliflozin (1) has been developed. This route involves ethyl C-aryl glycoside 9 as the key intermediate, which is easily crystallized and purified as the crystalline n-propanol solvate with high purity (>98.5%). The tetra-O-unprotected compound 9 could be directly reduced to crude dapagliflozin with high diastereoselectivity. The final pure API product 1 was isolated and purified with high purity (>99.7%). The process has been implemented on a multikilogram scale.
- Yu, Jun,Cao, Ying,Yu, Haizhou,Wang, Jinjia
-
p. 1458 - 1461
(2019/08/12)
-
- Preparation method suitable for industrial production of empagliflozin
-
The invention belongs to the technical field of organic synthesis route design and medicine and chemical engineering, particularly relates to a synthesis method of a sodium-glucose cotransporter 2(SGLT2) inhibitor, and more particularly relates to a preparation method of empagliflozin. The empagliflozin is synthesized by taking (3S)-3-[4-[(2-chloro-5-iodophenyl) methyl] phenoxy] tetrahydrofuran and glucono delta-lactone as initial raw materials through a series of substep reactions such as protection, addition, substitution, deprotection and reduction. In the synthesis steps disclosed by the invention, a staged target product does not need to be separated and purified after each step of reaction, and the target product is finally obtained by directly subjecting a high-purity reaction intermediate to subsequent steps. The preparation method is simple in process, simple and convenient to operate and good in industrial prospect.
- -
-
Paragraph 0040-0049
(2019/08/12)
-
- PROCESS FOR THE PREPARATION OF AMORPHOUS FORM OF CANAGLIFLOZIN
-
The present invention relates to an improved process for the preparation of amorphous form of Canagliflozin with high purity and high yield. Particularly the present invention is related to the direct isolation of amorphous form of Canagliflozin from reaction mixture and also related to purification of amorphous form of Canagliflozin through piperidine-4-carboxylic acid complex of Canagliflozin.
- -
-
Page/Page column 12
(2018/02/28)
-
- Carbon glucoside sodium glucose transport protein body 2 inhibitor
-
The invention relates to a carbon glucoside sodium glucose transport protein body 2 inhibitor, a preparation method and an application of the inhibitor. The carbon glucoside sodium glucose transport protein body 2 inhibitor has a structure as shown in general formula (I) as shown in the specification.
- -
-
Paragraph 0038; 0106-0108
(2018/07/30)
-
- Glucopyranosyl derivative and its use in medicine (by machine translation)
-
The invention relates to a as sodium-dependent glucose transporter (SGLTs) inhibitors of the glucopyranosyl derivative, containing the pharmaceutical composition and its use in medicine, in particular of formula (I) indicated by the glucopyranosyl derivative or its pharmaceutically acceptable salt or all of its stereoisomers, or containing the pharmaceutical composition and said derivative and pharmaceutical composition for the preparation of a medicine for treating diabetes and diabetes related diseases of the use. (by machine translation)
- -
-
Paragraph 0267; 0268; 0276; 0277
(2018/07/28)
-
- Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents
-
The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Therefore, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of NO donor and SGLT2 inhibitor were design to achieve dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the preferred hybrid 2 exhibited moderate SGLT2 inhibitory effects and anti-platelet aggregation activities, and its anti-platelet effect mediated by NO was also confirmed in the presence of NO scavenger. Moreover, compound 2 revealed significantly hypoglycemic effects and excretion of urinary glucose during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 2, is expected as a potential candidate for the intervention of cardiovascular complications in T2DM.
- Li, Zheng,Xu, Xue,Deng, Liming,Liao, Ruoxian,Liang, Ruiying,Zhang, Bo,Zhang, Luyong
-
p. 3947 - 3952
(2018/06/27)
-
- A PROCESS FOR THE PREPARATION OF D-GLUCITOL, 1,5-ANHYDRO-1-C-[4-CHLORO-3-[[4- [[(3S)-TETRAHYDRO-3-FURANYL]OXY]PHENYL]METHYL]PHENYL]-, ( 1 S)
-
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.
- -
-
Page/Page column 20; 21
(2018/09/28)
-
- Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof
-
The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.
- -
-
Paragraph 0054
(2019/01/04)
-
- Glucopyranosyl derivative preparation and medical application (by machine translation)
-
The invention relates to a as sodium-dependent glucose transporter (SGLT) inhibitors of the glucopyranosyl derivative and its application in medicine, in particular of formula (I) indicated by the 6 - oxa bicyclo [3.2.1] octane derivative or its pharmaceutically acceptable salt or all of its stereoisomers as a medicine for treating diabetes and diabetes related diseases. (by machine translation)
- -
-
Paragraph 0082; 0083; 0084; 0085; 0086
(2017/08/29)
-
- C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF
-
This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor. The C-aryl glycoside derivatives of this invention provides a new direction for the study of SGLT inhibitors.
- -
-
Paragraph 0096; 0115; 0116; 0117
(2017/04/19)
-
- Canagliflozin drug impurity as well as preparation method and application thereof
-
The invention discloses a canagliflozin drug impurity as well as a preparation method and application thereof. The invention provides a compound as well as a preparation method and application thereof. The method comprises the following steps: (1) enabling the compound as shown in formula 2 to be in contact with an alkaline lithium hydroxide aqueous solution to obtain a coarse product containing a compound as shown in formula 3, wherein the coarse product contains a compound as shown in formula 1; (2) crystallizing and filtering the coarse product to obtain mother liquor; (3) concentrating the mother liquor to obtain residues; and (4) crystallizing and filtering the residues in an L-proline-containing organic solvent, thus obtaining the compound as shown in formula 1. The method provided by the invention can realize directed preparation of the compound as shown in formula 1, and a reliable impurity contrast is provided for quality research on industrially produced canagliflozin-series diabetes treatment drug products and quantitative control over impurities.
- -
-
Paragraph 0053; 0054
(2017/10/31)
-
- Canagliflozin single crystal, method for preparing same and application of canagliflozin single crystal
-
The invention relates to a canagliflozin single crystal, a method for preparing the same and application of the canagliflozin single crystal. X-ray powder of the canagliflozin single crystal has characteristic peaks when the X-ray powder is diffracted at diffraction angles 2 theta of 7.95 degrees, 10.92 degrees, 13.94 degrees, 15.46 degrees, 15.94 degrees, 18.82 degrees, 20.27 degrees, 22.72 degrees and 26.78 degrees, the obtained single crystal is not reported, crystal structures of the canagliflozin single crystal are orthorhombic systems as shown by means of measurement, space groups are P2(1)2(1)2(1), and the numbers Z of molecules in crystal packs are 4. The canagliflozin single crystal, the method and the application have the advantages that the canagliflozin single crystal is a colorless needle crystal at the normal temperature and is excellent in morphology, and the purity of the canagliflozin single crystal can reach 99%; canagliflozin can be effectively separated from other impurities by the aid of the method, and the method is good in repeatability.
- -
-
Paragraph 0008; 0044; 0045; 0046; 0047; 0048
(2017/04/29)
-
- Empagliflozin monocrystalline and preparation method and purpose thereof
-
The invention relates to an Empagliflozin monocrystalline and a preparation method and a purpose thereof. A chemical structural formula of Empagliflozin is shown as a formula I, according to the Empagliflozin monocrystalline, the X-ray powder diffracting at the diffraction angles 2theta of 13.33, 14.66, 18.81, 20.33, 23.44, and 26.84 has characteristic peaks. A crystal structure of the Empagliflozin monocrystalline is a monoclinic system, the space group is C2, the number Z of molecules in crystal is 4, and the Empagliflozin monocrystalline is colorless sheet-shaped crystallization at normal temperature. The monocrystalline form is good, and the purity is as high as 99%.
- -
-
Paragraph 0040-0046
(2017/06/02)
-
- Synthesis of unlabelled and stable-isotope–labelled glucuronide metabolites of dapagliflozin and synthesis of stable-isotope–labelled dapagliflozin
-
Two regioisomeric glucuronide metabolites of dapagliflozin (BMS-512148) were synthesized and used to elucidate the structures of dapagliflozin metabolites observed in human urine samples. The structures of the synthetic metabolites were assigned by heteronuclear multiple-bond correlation, ROESY, and total correlation spectroscopy experiments. Analogues of these metabolites containing carbon-13 as a stable label were also prepared for use as internal standards for the analysis of urine samples obtained from patients participating in clinical studies.
- Cao, Kai,Brailsford, John A.,Yao, Ming,Caceres-Cortes, Janet,Espina, Robert,Bonacorsi, Samuel J.
-
p. 150 - 159
(2017/03/16)
-
- PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF
-
The present invention relates to a process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula-1 and its glycerol solvate.
- -
-
Paragraph 0079-0080
(2017/02/24)
-
- PREMIX OF DAPAGLIFLOZIN AND PROCESS FOR THE PREPARATION THEREOF
-
The present invention relates to a premix of dapagliflozin with lactose, processes for its preparation, and pharmaceutical composition thereof. The invention also relates to a process for the preparation of an amorphous dapagliflozin and crystalline dapagliflozin propanediol hydrate.
- -
-
Page/Page column 34
(2017/08/01)
-
- Industrial preparation method for empagliflozin
-
The invention discloses an industrial preparation method for empagliflozin. Specifically, the invention relates to a preparation method for empagliflozin as shown in formula as defined in the specification, i.e., (1S)-1,5-dehydro-1-(4-chloro-3{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}pheyl)-D-glucitol, and an intermediate prepared by using the method. The preparation method for empagliflozin in the invention is stable in process, good in reproducibility and suitable for large-scale production.
- -
-
Paragraph 0034
(2017/08/27)
-
- PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN AND ITS SOLVATE THEREOF
-
The present invention provides for crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The present invention also provides industrial methods for production of crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline 5 Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The present invention further provides an industrial method production of amorphous Dapagliflozin.
- -
-
Page/Page column 17
(2018/04/11)
-
- PROCESS FOR PREPARATION OF DAPAGLIFLOZIN
-
The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
- -
-
Paragraph 0191
(2016/11/21)
-
- A NOVEL PROCESS FOR PREPARING (2S,3R,4R,5S,6R)-2-{3-[5-[4-FLUORO-PHENYL)- THIOPHEN-2-YLMETHYL]-4-METHYL-PHENYL}-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,4,5- TRIOL AND ITS STABLE AMORPHOUS HEMIHYDRATE FORM
-
The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-{3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol and its stable amorphous hemihydrate form.
- -
-
Page/Page column 15
(2016/09/26)
-
- A GLUCOPYRANOSYL DERIVATIVE AND PREPARATION METHOD AND USES THEREOF
-
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compound and their uses for treating diabetes and diabetes-related diseases. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, easy purification, and is suitable for industrial production.
- -
-
Paragraph 00138; 00139
(2016/11/17)
-
- Development of a Scalable Synthesis of Tofogliflozin
-
An efficient and scalable synthesis of an antidiabetic drug, tofogliflozin (1), which was identified as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is described. A key factor in the synthesis of 1 was the selection of the purpose-designed protecting group, which plays a strategic role in protection, chemoselective activation, and crystalline purification. The developed and optimized method made it possible to prepare 1 on a multidecagram scale without any column chromatography.
- Ohtake, Yoshihito,Emura, Takashi,Nishimoto, Masahiro,Takano, Koji,Yamamoto, Keisuke,Tsuchiya, Satoshi,Yeu, Sang-Yong,Kito, Yasushi,Kimura, Nobuaki,Takeda, Sunao,Tsukazaki, Masao,Murakata, Masatoshi,Sato, Tsutomu
-
p. 2148 - 2153
(2016/03/15)
-
- C - aryl glucoside SGLT2 inhibitor
-
The invention relates to the field of medicines related to diabetes mellitus and particularly relates to a 2-type sodium-glucose co-transporter (SGLT2) inhibitor with a multi-aryl glucoside structure and shown as the specification, a preparation method thereof, a medicine composition taking the compound as an active components and an application thereof in preparing medicines for resisting diabetes mellitus.
- -
-
Paragraph 0223-0225
(2017/04/28)
-
- Antidiabetic compound and preparation method and application thereof
-
The invention discloses an antidiabetic compound and a preparation method and application thereof, and belongs to the technical field of medicine. The chemical structure of the compound is shown as a formula (I) (please see the formula in the description), wherein R is selected from i-Pr, Cl and COCH2Cl. According to the antidiabetic compound and the preparation method and application thereof, 2-chloro-5-bromobenzoic acid and D-gluconolactone are taken as starting raw materials, and three Dapagliflozin derivatives are finally obtained through reacting; the optimal reaction condition of different positioning groups is determined according to the reaction conditions of a Friede-Crafts alkylation reaction of the different positioning groups; in addition, a novel stereoisomerism splitting method is applied, therefore, the reaction conditions are optimized, the reaction cost is greatly lowered, the yield is increased, the used raw materials are cheap and easy to obtain, and the wide applicability is achieved.
- -
-
Paragraph 0065; 0066; 0067
(2017/09/19)
-
- An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue
-
A convenient method for highly diastereoselective synthesis of bexagliflozin 7a and its carbon-13 labeled analogue 7b was developed. The main feature is the stereoselective reduction of 16 catalyzed by BF3·OEt2. Furthermore, the cocrystallization skill was firstly used for the purification of bexagliflozin and its analogue. The carbon-13 labeled bexagliflozin 7b was firstly prepared in five steps and in 57% overall chemical yield starting from the commercially available D-gluconolactone-[13C6].
- Xu, Ge,Xu, Baihua,Song, Yanli,Sun, Xun
-
p. 4684 - 4687
(2016/09/28)
-
- Defluorinated canagliflozin compound, and preparation method and application thereof
-
The invention relates to a defluorinated canagliflozin compound as shown in a formula (I) which is described in the specification, and a preparation method thereof. Moreover, the invention also provides application of defluorinated canagliflozin as a standard reference substance. According to the invention, the quality of a canagliflozin product is effectively controlled, so safety and validity of a canagliflozin preparation in clinical usage are guaranteed.
- -
-
Paragraph 0040
(2016/12/16)
-
- Deuterium-modified carbon glycoside derivate
-
The invention belongs to the field of medinal chemistry and relates to a deuterium-modified carbon glycoside derivate, in particular to a compound shown in the formula I. The invention further relates to a preparation method of the deuterium-modified carbon glycoside derivate, a medicine composition comprising the deuterium-modified carbon glycoside derivate and application of the deuterium-modified carbon glycoside derivate or the medicine composition thereof for preparing medicine for treating diabetes.
- -
-
Paragraph 0076; 0078
(2016/12/26)
-
- Glucopyranosyl derivative and application thereof in medicines
-
The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.
- -
-
Paragraph 0179; 0193; 0194; 0195
(2016/10/08)
-
- Method for preparing derivatives of spiroketal
-
Provided is a process for the preparation of a spiroketal derivative via a compound represented by general formula (II) [wherein each variable group and each variable number are as defined in the description].
- -
-
Paragraph 0276-0280
(2016/10/07)
-
- Compound canagliflozin diformin tablet
-
The invention relates to a compound canagliflozin diformin tablet which comprises the following components in parts by weight: 100 parts of metformin hydrochloride, 2-4 parts of canagliflozin and 30-100 parts of pharmaceutically acceptable excipients, wherein the pharmaceutically acceptable excipients comprise a filling agent, a disintegrating agent, an adhesive, an alkaline agent and a lubricating agent. According to the invention, the canagliflozin and diformin are combined to be prepared into a compound drug, due to the synergistic effect of canagliflozin and diformin, the compound canagliflozin diformin tablet has a good effect of treating type II diabetes, does not have any obvious side reaction and has great application prospects.
- -
-
Paragraph 0028; 0030; 0033
(2017/01/19)
-
- card Geleg net bulk drug and preparation (by machine translation)
-
The invention relates to a net card Geleg bulk drug and preparation, the preparation method of states card Geleg net raw material comprises a compound 1 With TMSCI, N - methyl morpholine reaction to produce compound CAN - C Compound CAN - A With a compound CAN - C, MeOH reaction to produce the compound E Compound E, acetic anhydride, N - methyl morpholine and DMAP mixing, reaction to produce the compound F Add triethyl silane, boron trifluoride ether, acetonitrile and water mixing, reaction to produce compound CAN - G Namely card Geleg net bulk drug. The preparation comprises the following weight percentage of each component: card Geleg net bulk drug, microcrystalline cellulose, anhydrous lactose, or microcrystalline cellulose aqueous solution, sodium carboxy methyl cellulose, magnesium stearate. The card gliclazide net of the raw material preparation method has high reaction yield, reagent is easy to get the advantages of the raw materials, greatly reduces the production cost of the card Geleg net raw material. (by machine translation)
- -
-
Paragraph 0026; 0028; 0029; 0030
(2017/05/27)
-
- GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE
-
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or pharmaceutically acceptable salts or all stereisomers thereof, pharmaceutical composition containing the derivatives and their uses for treatment of diabetic and diabetes-related diseases.
- -
-
Paragraph 00113
(2015/04/15)
-
- OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE
-
The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)
- -
-
Paragraph 0084
(2015/07/15)
-
- Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
-
The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity) or
- -
-
Paragraph 0051; 0051
(2015/07/15)
-
- OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE
-
The present invention relates to a pharmaceutical technology, and more specifically, to optically pure benzyl-4-chloro-phenyl glucoside derivatives represented by the chemical formula II and III or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the compounds and intermediates thereof, pharmaceutical formulations and pharmaceutical compositions containing the compounds, and the use of the optically pure benzyl-4-chloro-phenyl glucoside derivatives as sodium glucose co-transporter (SGLT) inhibitors for the prevention and treatment of the diabetes including the insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus and the diabetes-related deseases such as insulin-resistant diseases and obesity.COPYRIGHT KIPO 2015
- -
-
Paragraph 0166-0168
(2016/11/24)
-
- Design, Synthesis and in vivo Evaluation of Novel C-Aryl Glucosides as Potent Sodium-Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes
-
A series of novel C-aryl glucosides with substituents at the 3′-position or cyclization at 3′, 4′-positions of the distal aryl ring were designed and synthesized, which might decrease the oxidative metabolism of dapagliflozin. Preliminary evaluation for hypoglycemic effect and the risk of hypoglycemia were carried out both in normal and in streptozotocin-induced diabetic mice. Among the synthesized compounds, compound 19a exerted potency-similarity with dapagliflozin and triggered the hypoglycemic effect in a dose-dependent manner. Besides, compound 19a, even at the high dose of 10 mg/kg, revealed a low risk of hypoglycemia. In further studies, 19a exhibited sustained antihyperglycemic effect without particular side-effects in 30-day chronic diabetic mice studies. Moreover, histological changes in the pancreas of diabetic mice indicated 19a might protect pancreatic β-cell from apoptosis by reducing the damage of glucotoxicity. All of these results demonstrated that compound 19a, with excellent in vivo pharmacological activity and safety profile, was considered to be a promising drug candidate for the treatment of diabetes mellitus.
- Li, Zheng,Wang, Xuekun,Xu, Xue,Qiu, Qianqian,Jiao, Lei,Huang, Wenlong,Qian, Hai
-
p. 764 - 775
(2015/03/30)
-
- PROCESS FOR PREPARATION OF CANAGLIFLOZIN
-
The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.
- -
-
Paragraph 0193; 0194
(2015/12/17)
-
- Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof
-
Disclosed is a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein R1 and R2 are each independently hydrogen, —OH, alkyl, —CF3, —OCHF2, —OCF3 or halogen; R3 is cycloalkyl, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or —OCH2CH3; R4 is hydrogen, —OH, —O aryl, —OCH2 aryl, alkyl, cycloalkyl, —CF3, —OCHF2, —OCF3, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or halogen; A is —CX1X2, wherein X1 and X2 are each independently H, F and Cl, and when both X1 and X2 are H, R3 is not —OCH2CH3. The compound has an activity of inhibitors of sodium-dependent glucose transport protein. Also disclosed is a method for preparing the compound, a pharmaceutical composition comprising the compound, use of the compound and pharmaceutical composition thereof in preparing medicaments of SGLT2 inhibitors and treating related diseases.
- -
-
Paragraph 0070; 0071
(2014/03/24)
-
- C-GLYCOSIDE DERIVATIVES
-
The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R1, R2, R3, R4, R5a, R5b, R5c and X are defined as in the description.
- -
-
Paragraph 0096; 0097
(2014/05/20)
-
- C-GLYCOSIDE DERIVATIVES
-
The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R1, R2, R3, R4, R5a, R5b, R5c and X are defined as in the description.
- -
-
Paragraph 0079-0080
(2014/05/20)
-
- PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS
-
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
- -
-
Page/Page column 0297-0301
(2013/10/22)
-
- PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS
-
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
- -
-
Paragraph 0242; 0243; 0244
(2013/11/05)
-
- PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS
-
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter (SGLT) and synthetic intermediates useful for preparing such compounds.
- -
-
Paragraph 0259; 0260
(2013/11/05)
-